Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

Go back to Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
(NASDAQ: AVIR) Delayed: 5.43 --0 (-0%)
Previous Close $5.43    52 Week High $2.00 
Open $5.43    52 Week Low $1.15 
Day High $5.43    P/E N/A 
Day Low $5.43    EPS $0.00 
Volume 15,258